A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Phase I Clinical Study to Assess the Safety, Pharmacokinetics, and Immunogenicity of HLX6018 in Healthy Subjects
Condition(s):IPFLast Updated:March 15, 2024Not yet recruiting
Hide Studies Not Open or Pending
Condition(s):IPFLast Updated:March 15, 2024Not yet recruiting
Condition(s):Periodontitis; Gingivitis; Periodontal HealthLast Updated:October 31, 2023Completed
Condition(s):GliomaLast Updated:February 16, 2017Completed
Condition(s):Enteral Feeding Intolerance; Necrotizing Enterocolitis; Late-Onset Neonatal SepsisLast Updated:July 12, 2022Completed
Condition(s):Proliferative Diabetic RetinopathyLast Updated:May 19, 2021Completed
Condition(s):Geographic Atrophy; Age-related Macular DegenerationLast Updated:September 18, 2019Completed
Condition(s):Hip Osteoarthritis; Hip Impingement Syndrome; Cartilage Damage; FibrosisLast Updated:October 30, 2023Terminated
Condition(s):Head and Neck Squamous Cell Carcinoma; Quality of Life; Radiotherapy; ComplicationsLast Updated:July 25, 2022Terminated
Condition(s):Allergic RhinitisLast Updated:March 16, 2023Recruiting
Condition(s):Early Lumbar Disc DegenerationLast Updated:February 26, 2016Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.